Cargando…

Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients

BACKGROUND: Glioma is a deadly and immunosuppressive brain tumour. Complement C1r subcomponent like (C1RL), a prognostic biomarker in several kinds of tumours, has attracted increasing attention from oncologists. However, the role of C1RL in glioma remains unclear. METHODS: Through analysis of 2120...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junyou, Tong, Luqing, Lin, Gaojun, Wang, Hui, Zhang, Liang, Yang, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526369/
https://www.ncbi.nlm.nih.gov/pubmed/32993564
http://dx.doi.org/10.1186/s12885-020-07436-6
_version_ 1783588860343615488
author Wang, Junyou
Tong, Luqing
Lin, Gaojun
Wang, Hui
Zhang, Liang
Yang, Xuejun
author_facet Wang, Junyou
Tong, Luqing
Lin, Gaojun
Wang, Hui
Zhang, Liang
Yang, Xuejun
author_sort Wang, Junyou
collection PubMed
description BACKGROUND: Glioma is a deadly and immunosuppressive brain tumour. Complement C1r subcomponent like (C1RL), a prognostic biomarker in several kinds of tumours, has attracted increasing attention from oncologists. However, the role of C1RL in glioma remains unclear. METHODS: Through analysis of 2120 glioma patients from 5 public datasets, the relationships between C1RL expression and clinicopathological characteristics were evaluated. Furthermore, the C1RL-associated genes were screened, and Gene Ontology (GO) analysis was conducted to investigate biological process enrichment. In addition, tumour purity, leukocyte infiltration and overall survival were evaluated based on C1RL expression. RESULTS: We found that C1RL expression was upregulated in glioblastoma (GBM), especially mesenchymal GBM and primary GBM. Increased C1RL expression accompanied the IDH1-wt phenotype in both lower grade glioma (LGG) and GBM. C1RL- associated genes were mainly enriched in biological processes related to the immune response. C1RL expression was also correlated with reduced tumour purity and increased M2 macrophage infiltration. Higher C1RL expression predicted unfavourable survival in patients with glioma and therapeutic resistance in GBM. CONCLUSIONS: Our results imply that C1RL is involved in immunological activities and is an independent unfavourable prognostic biomarker in patients with glioma. C1RL is a potential clinical immunotherapeutic target for glioma treatment in the future.
format Online
Article
Text
id pubmed-7526369
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75263692020-10-01 Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients Wang, Junyou Tong, Luqing Lin, Gaojun Wang, Hui Zhang, Liang Yang, Xuejun BMC Cancer Research Article BACKGROUND: Glioma is a deadly and immunosuppressive brain tumour. Complement C1r subcomponent like (C1RL), a prognostic biomarker in several kinds of tumours, has attracted increasing attention from oncologists. However, the role of C1RL in glioma remains unclear. METHODS: Through analysis of 2120 glioma patients from 5 public datasets, the relationships between C1RL expression and clinicopathological characteristics were evaluated. Furthermore, the C1RL-associated genes were screened, and Gene Ontology (GO) analysis was conducted to investigate biological process enrichment. In addition, tumour purity, leukocyte infiltration and overall survival were evaluated based on C1RL expression. RESULTS: We found that C1RL expression was upregulated in glioblastoma (GBM), especially mesenchymal GBM and primary GBM. Increased C1RL expression accompanied the IDH1-wt phenotype in both lower grade glioma (LGG) and GBM. C1RL- associated genes were mainly enriched in biological processes related to the immune response. C1RL expression was also correlated with reduced tumour purity and increased M2 macrophage infiltration. Higher C1RL expression predicted unfavourable survival in patients with glioma and therapeutic resistance in GBM. CONCLUSIONS: Our results imply that C1RL is involved in immunological activities and is an independent unfavourable prognostic biomarker in patients with glioma. C1RL is a potential clinical immunotherapeutic target for glioma treatment in the future. BioMed Central 2020-09-29 /pmc/articles/PMC7526369/ /pubmed/32993564 http://dx.doi.org/10.1186/s12885-020-07436-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wang, Junyou
Tong, Luqing
Lin, Gaojun
Wang, Hui
Zhang, Liang
Yang, Xuejun
Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients
title Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients
title_full Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients
title_fullStr Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients
title_full_unstemmed Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients
title_short Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients
title_sort immunological and clinicopathological characteristics of c1rl in 2120 glioma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526369/
https://www.ncbi.nlm.nih.gov/pubmed/32993564
http://dx.doi.org/10.1186/s12885-020-07436-6
work_keys_str_mv AT wangjunyou immunologicalandclinicopathologicalcharacteristicsofc1rlin2120gliomapatients
AT tongluqing immunologicalandclinicopathologicalcharacteristicsofc1rlin2120gliomapatients
AT lingaojun immunologicalandclinicopathologicalcharacteristicsofc1rlin2120gliomapatients
AT wanghui immunologicalandclinicopathologicalcharacteristicsofc1rlin2120gliomapatients
AT zhangliang immunologicalandclinicopathologicalcharacteristicsofc1rlin2120gliomapatients
AT yangxuejun immunologicalandclinicopathologicalcharacteristicsofc1rlin2120gliomapatients